Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 42Lymphoma 37Lymphoma, Mantle-Cell 35Lymphoma, Non-Hodgkin 32Multiple Myeloma 30Lymphoma, Follicular 30Hodgkin Disease 23Recurrence 19Lymphoma, Large B-Cell, Diffuse 19Lymphoma, B-Cell, Marginal Zone 18Waldenstrom Macroglobulinemia 12Leukemia 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, B-Cell 9Neoplasms, Plasma Cell 7Lymphoma, T-Cell 6Leukemia, Myeloid, Acute 6Burkitt Lymphoma 6Myelodysplastic Syndromes 5Leukemia, B-Cell 5Hematologic Neoplasms 5Sezary Syndrome 4Neoplasms 4Mycosis Fungoides 4Immune System Diseases 4Small Cell Lung Carcinoma 3Neoplasm Metastasis 3Myeloproliferative Disorders 3Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell, Cutaneous 3

Interventions

venetoclax 1pomalidomide 1ixazomib 1daratumumab 1Dexamethasone 1Calcium Dobesilate 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Proteostasis Deficiencies × Bendamustine Hydrochloride × Clear all
NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡